Dexmedetomidine reduces acute kidney injury in high-risk but not low-risk patients after non-cardiac surgery: secondary analysis of a randomized controlled trial
Journal of Anesthesia · 2026
DOI: 10.1007/s00540-026-03661-8 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Anesthesia, 2026. Verfasst von Xin-Quan Liang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, 100034, China. Hauptthemen laut MEDLINE: Dexmedetomidine, Acute Kidney Injury, Postoperative Complications, Adrenergic alpha-2 Receptor Agonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Purpose
Acute kidney injury (AKI) is a significant postoperative complication associated with poor long-term outcomes. Dexmedetomidine, a selective α₂-adrenergic agonist with anti-inflammatory properties, may protect the kidney during non-cardiac surgery. This study examined whether intraoperative dexmedetomidine reduces AKI in both high-risk and low-risk patients.
Methods
This was a secondary analysis of a randomized double-blind placebo-controlled trial. Patients aged ≥ 60 years scheduled for elective non-cardiac surgery expected to last ≥ 2 h under general anesthesia were enrolled and classified as low-risk or high-risk using the General Surgery Acute Kidney Injury Risk Index. Participants were randomly allocated to receive intraoperative dexmedetomidine (loading dose 0.6 μg/kg over 10 min before induction, followed by 0.5 μg/kg/h until 1 h before surgery end) or normal saline. The primary endpoint was AKI incidence within 7 postoperative days.
Results
Among high-risk patients, AKI occurred in 12.6% (13/103) of the dexmedetomidine group versus 23.4% (25/107) of controls (RR 0.54, 95% CI 0.29 to 1.00, P = 0.043); after multivariable adjustment, dexmedetomidine remained independently associated with lower AKI risk (OR 0.44, 95% CI 0.20 to 0.98, P = 0.045). In contrast, low-risk patients showed no significant difference with or without dexmedetomidine (7.9% vs 9.6%; RR 0.82, 95% CI 0.44 to 1.55, P = 0.543; adjusted OR 0.65, 95% CI 0.30 to 1.38, P = 0.260). Urological surgery was an independent predictor of AKI across the entire cohort.
Conclusion
Intraoperative dexmedetomidine was associated with lower risk of AKI in high-risk but not in low-risk patients undergoing non-cardiac surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, 100034, China.
- Department of Anesthesiology, Peking University First Hospital, No. 8 Xishiku St., Xicheng District, Beijing, 100034, China. gogolion02@bjmu.edu.cn.
Förderung
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Liang, X. Q., Li, M. L., & Li, C. J. (2026). Dexmedetomidine reduces acute kidney injury in high-risk but not low-risk patients after non-cardiac surgery: secondary analysis of a randomized controlled trial. Journal of Anesthesia. https://doi.org/10.1007/s00540-026-03661-8
Vancouver
Liang XQ, Li ML, Li CJ. Dexmedetomidine reduces acute kidney injury in high-risk but not low-risk patients after non-cardiac surgery: secondary analysis of a randomized controlled trial. Journal of Anesthesia. 2026. doi:10.1007/s00540-026-03661-8
BibTeX
@article{Liang2026,
author = {Liang, Xin-Quan and Li, Mei-Lin and Li, Chun-Jing},
title = {Dexmedetomidine reduces acute kidney injury in high-risk but not low-risk patients after non-cardiac surgery: secondary analysis of a randomized controlled trial},
journal = {Journal of Anesthesia},
year = {2026},
doi = {10.1007/s00540-026-03661-8}
}
EUVIMED